CONTEXT: due to the central role of metabolic abnormalities in the pathophysiology of PCOS, insulin sensitising agents have been proposed as a feasible treatment option. OBJECTIVE: to investigate which is the more effective between metformin and myoinositol on hormonal, clinical and metabolic parameters in obese patients with polycystic ovary syndrome (PCOS). STUDY DESIGN: crossover randomized-controlled study. PATIENTS: Thirty-four PCOS obese women (age: 25.62 ± 4.7 years; BMI: 32.55 ± 5.67 kg/m2 ) were randomized to receive metformin (850 mg twice a day) or myoinositol (1000 mg twice a day) for six months. After a three month washout, the same subjects received the other compound for the following six months. MEASUREMENTS: Ultrasonographic pelvic examinations, hirsutism score, anthropometric and menstrual pattern evaluation, hormonal profile assays, oral glucose tolerance test (OGTT) and lipid profile at baseline and after 6 months of treatment were performed. RESULTS: Both metformin and myoinositol significantly reduced the insulin response to OGTT and improved insulin sensitivity. Metformin significantly decreased body weight, and improved menstrual pattern and Ferriman-Gallwey score. Metformin treatment was also associated with a significant decrease in LH and estradiol levels, androgens and AMH levels. None of these clinical and hormonal changes were observed during myoinositol administration. CONCLUSIONS: Both treatments improved the glyco-insulinaemic features of obese PCOS patients,but only metformin seems to exert a beneficial effect on the endocrine and clinical features of the syndrome. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.

Tagliaferri, V., Romualdi, D., Immediata, V., De Cicco, S., Di Florio, C., Lanzone, A., Guido, M., Metformin versus myoinositol: which is better in obese PCOS patients? A randomized controlled crossover study., <<CLINICAL ENDOCRINOLOGY>>, 2017; (Jan 16): ---. [doi:10.1111/cen.13304] [http://hdl.handle.net/10807/92694]

Metformin versus myoinositol: which is better in obese PCOS patients? A randomized controlled crossover study.

Tagliaferri, Valeria
Primo
;
Romualdi, Daniela
Secondo
;
Immediata, Valentina
;
De Cicco, Simona;Di Florio, Christian;Lanzone, Antonio
Penultimo
;
Guido, Maurizio
Ultimo
2017

Abstract

CONTEXT: due to the central role of metabolic abnormalities in the pathophysiology of PCOS, insulin sensitising agents have been proposed as a feasible treatment option. OBJECTIVE: to investigate which is the more effective between metformin and myoinositol on hormonal, clinical and metabolic parameters in obese patients with polycystic ovary syndrome (PCOS). STUDY DESIGN: crossover randomized-controlled study. PATIENTS: Thirty-four PCOS obese women (age: 25.62 ± 4.7 years; BMI: 32.55 ± 5.67 kg/m2 ) were randomized to receive metformin (850 mg twice a day) or myoinositol (1000 mg twice a day) for six months. After a three month washout, the same subjects received the other compound for the following six months. MEASUREMENTS: Ultrasonographic pelvic examinations, hirsutism score, anthropometric and menstrual pattern evaluation, hormonal profile assays, oral glucose tolerance test (OGTT) and lipid profile at baseline and after 6 months of treatment were performed. RESULTS: Both metformin and myoinositol significantly reduced the insulin response to OGTT and improved insulin sensitivity. Metformin significantly decreased body weight, and improved menstrual pattern and Ferriman-Gallwey score. Metformin treatment was also associated with a significant decrease in LH and estradiol levels, androgens and AMH levels. None of these clinical and hormonal changes were observed during myoinositol administration. CONCLUSIONS: Both treatments improved the glyco-insulinaemic features of obese PCOS patients,but only metformin seems to exert a beneficial effect on the endocrine and clinical features of the syndrome. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
Inglese
Tagliaferri, V., Romualdi, D., Immediata, V., De Cicco, S., Di Florio, C., Lanzone, A., Guido, M., Metformin versus myoinositol: which is better in obese PCOS patients? A randomized controlled crossover study., <<CLINICAL ENDOCRINOLOGY>>, 2017; (Jan 16): ---. [doi:10.1111/cen.13304] [http://hdl.handle.net/10807/92694]
File in questo prodotto:
File Dimensione Formato  
92694.pdf

non disponibili

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Non specificato
Dimensione 111.56 kB
Formato Unknown
111.56 kB Unknown   Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/92694
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 18
social impact